NCT07446439

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 280 (estimated)
• Sponsor: Vanda Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Conditions

• Nausea and Vomiting
• Obesity

Interventions

Type	Name	Description
DRUG	Tradipitant	Oral Capsule
DRUG	Placebo	Oral Capsule

Timeline

• Start date: 2026-02-25
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2026-03-03
• Last updated: 2026-03-03

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study